Antifibrotic Pirfenidone in Patients With Progressive Pulmonary Fibrosis
Is the antifibrotic pirfenidone an effective and safe therapy for individuals with progressive pulmonary fibrosis?
Is the antifibrotic pirfenidone an effective and safe therapy for individuals with progressive pulmonary fibrosis?
What characterizes the progressive fibrosing ILD phenotype, and what baseline factors associated with this phenotype may help guide clinical decision making?
Are patients with fibrotic interstitial lung disease at risk of malignancy when treated with the immunomodulatory drugs MMF and AZA?
Researchers assessed whether BMI and weight loss are reliable prognostic indicators in patients with fibrotic interstitial lung disease.
A review of 21 studies evaluated the long-term outcomes associated with pulmonary rehabilitation for patients with pulmonary fibrosis, including ILD.
The researchers sought to identify predictors of disease progression and mortality in non-IPF fILD using criteria from the INBUILD, RELIEF, and uILD trials.
Because the 2 antifibrotics in use — pirfenidone and nintedanib — have differing mechanisms of action, when one is ineffective the other may provide benefit, thus improving survival.
Trimethoprim-sulfamethoxazole therapy did not reduce time to death, lung transplant, or hospitalization in patients with moderate or severe idiopathic pulmonary fibrosis.
The understanding of the role of specific molecular mechanisms causing pulmonary hypertension in people with pulmonary fibrosis is growing but still in its infancy.
Metformin was effective in reducing pulmonary fibrosis in human IPF fibroblasts and when used in combination with low-dose nintedanib, demonstrated a synergistic, antifibrotic effect.